Drug Trial Radar · NCT07010497
A Prospective Study to Evaluate the Safety and Efficacy of the Combination Therapy of Irpagratinib, Atezolizumab, and Bevacizumab in Patients With Hepatocellular Carcinoma
Last checked: Nov 20, 2026Latest source record: Jul 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
33
Planned (sponsor's estimate)
Start
Mar 16, 2026
Primary completion
Mar 31, 2029
Study completion Mar 31, 2029
Sponsor
- Lead sponsor
- Asan Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Abbisko Therapeutics Co, Ltd
- First posted
- Jun 8, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 2, open-label study to evaluate the safety, tolerability and efficacy of Irpagratinib in combination with Atezolizumab and Bevacizumab in patients with advanced or unresectable HCC harboring FGF19 overexpression. This study composes two parts, a Safety Run-in part to evaluate safety and establish the dose of Irpagratinib for the triple combination, and an Expansion part to evaluate the preliminary efficacy and safety using Simon's two-stage design.
Conditions
- Carcinoma, Hepatocellular
Interventions
irpagratinibDrug
Patients will receive oral administration of ABSK-011 capsules in a repetitive dosing regimen for a period of 21 consecutive days as a cycle, either once daily or twice daily, until the investigators make a comprehensive assessment of imaging examinations, laboratory data, and the clinical condition of the patients, and determine that there is intolerable toxicity or disease progression.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of DLTsTime frame: Safety Run-in: At the end of Cycle 1 (each cycle is 21 days)
- Objective response rate (ORR)Time frame: through study completion, an average 21months
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Asan Medical Center,
Seoul, South Korea · Recruiting
Seoul National University Hospital
Seoul, South Korea · Not yet recruiting
Severance Hospital
Seoul, South Korea · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.